Openbookopenbook
Equity
INCY
+0.0 · +0.00%
USD · NASDAQ

Incyte Corporation(INCY) Stock Analysis | Healthcare

USD --+0.00%
Reward71High
Risk21Low
75%Data
Strong 28% profit margin · Revenue growing 38% YoY
Quality Compounder
Market Cap:25.91Bn
ⓘ
Reward Rating
71
High
Reward Assessment
75% data coverage
Top 25% of stocksView factors
ⓘ
Risk Rating
21
Low
Risk Assessment

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on INCY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for INCY, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $127.13.

What is Incyte Corporation?

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.

INCY · Verdict

Strong reward · low risk

INCY scores well on profitability and cash flow with no major weaknesses flagged in the model.

Based on 88% data coverage

INCY · Verdict

What’s working & what to watch

Strengths 5

  • Profitability97/100

    25% net margin · 31% ROE

  • Cash flow95/100

    26% free-cash-flow margin

  • Balance sheet92/100

    Interest covered 686.5×

  • Growth79/100

    Rev +14.8% CAGR · earnings +55.7%

  • Volatility65/100

    Above average

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Incyte Corporation?

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 25.91B, and a P/E ratio of 16.3x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: High (71)

The scoring profile indicates a strong reward potential, driven primarily by profitability and growth. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

ROIVLarge Cap / 26.1B market cap
Roivant Sciences Ltd
Compare
MRNALarge Cap / 25.3B market cap
Moderna Inc
Compare
INSMLarge Cap / 27.5B market cap
Insmed Inc
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap25.91B
P/E Ratio16.2815
Dividend YieldN/A
Beta0.769
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
237,334 shares
$3.6M
0
6-9months
795,225 shares
$9.5M
0
9-12months
44,227 shares
$396k
0
3 disclosures without share count
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.